Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting

PR Newswire/Les Echos/

PRESS RELEASE

Sanofi Compounds to be Featured in 178 Abstracts at American Society of

Hematology Annual Meeting

- Scientific presentations include Sanofi JAK2 inhibitor, Clolar(r)/Evoltra(r),

                 Elitek(r), Mozobil(r) and Thymoglobuline(r) -

Paris, France - December 3, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY)
announced today that new research spanning the company's marketed and
investigational hematology products, including its late-stage selective JAK2
inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual
Meeting of the American Society of Hematology in Atlanta, GA., 
December 8-11, 2012.

"We have a strong commitment to developing treatment solutions for patients 
with difficult-to-treat blood cancers where there remains unmet medical need," 
said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi 
Oncology. "At this year's ASH, we unveil for the hematology community our 
selective JAK2 inhibitor, which we are investigating to fill existing treatment
gaps in myelofibrosis. We look forward to the results of our Phase III trial 
in 2013."

Abstracts to be presented at the meeting cover the latest research on Sanofi
Oncology's marketed hematology products Clolar(r)/Evoltra(r), Elitek(r),
Mozobil(r) and Thymoglobuline(r) as well as the novel, investigational 
selective JAK2 inhibitor (SAR302503). Sanofi Oncology's JAK2 inhibitor is in 
clinical development for the treatment of the three main types of 
myeloproliferative neoplasms: primary myelofibrosis (MF), polycythemia vera 
(PV) and essential thrombocythemia (ET).

Key abstracts to be presented at ASH include:
  * A Phase II randomized dose-ranging study of the JAK2 selective inhibitor
    SAR302503 in patients with intermediate-2 or high-risk primary 
    myelofibrosis, post-polycythemia vera MF or post-essential throm 
    bocythemia MF
     o Presenter: Moshe Talpaz, M.D., University of Michigan, USA
     o Poster #2837, Sunday December 9, 6:00pm - 8:00pm, Hall B1-B2, Building B

  * Analysis of the impact and burden of illness of polycythemia vera and
    essential thrombocythemia in the US
     o Presenter: Jyotsna Mehta, Sanofi, Cambridge, USA
     o Poster #2071; Saturday, December 8, 5:30pm - 7:30 pm, Hall B1-B2, 
       Building B

  * Epidemiology of myelofibrosis, polycythemia vera and essential 
    thrombocythemia in the European Union
     o Odile Moulard, Sanofi, Chilly Mazarin, France
     o Poster #1744, Saturday, December 8, 5:30 pm - 7:30 pm, Hall B1-B2,
       Building B

  * Epidemiology of myeloproliferative disorders in US - a real world analysis
     o Presenter: Ruben Mesa, M.D., Mayo Clinic Arizona, USA
     o Poster #2834; Sunday, December 9, 6:00pm - 8:00 pm, Hall B1-B2, 
       Building B 

  * Analysis of the impact and burden of illness of myelofibrosis in the US
     o Presenter: Hongwei Wang, Sanofi, Bridgewater, USA
     o Oral presentation #972; Tuesday, December 11, C211-C213, Building C

About the Sanofi JAK2 Inhibitor
JAK2 is a key enzyme for blood cell development. Mutations in JAK2 can lead to
dysregulated JAK2 signaling and are thought to be a cause of MF. Patients with
wild type JAK2 have also been shown to have persistent, dysregulated activation
of the JAK2 signaling pathway, which may be caused by mutations in other
proteins believed to drive the development of the disease. In early clinical
studies, the Sanofi JAK2 inhibitor has shown activity in MF patients with both
wild type and mutated (JAK2V617F) JAK2.

About Clolar(r)/Evoltra(r)
Approved in 49 countries, Clolar/Evoltra is for the treatment of pediatric
patients with relapsed or refractory acute lymphoblastic leukemia (ALL) after 
at least two prior treatment options. Randomized trials demonstrating increased
survival or other clinical benefit have not been conducted. Clolar/Evoltra was
the first chemotherapy in more than a decade approved specifically for children
with ALL.

About Mozobil(r)
Approved in 42 countries, Mozobil rapidly and effectively increases the number
of hematopoietic stem cells in the blood to prepare non-Hodgkin's lymphoma and
multiple myeloma patients for an autologous hematopoietic stem cell transplant.
Mozobil is used with another medication (G-CSF) to release hematopoietic stem
cells from the bone marrow into the bloodstream by disrupting a bond that
normally keeps stem cells anchored to the bone marrow.

About Thymoglobuline(r)
For the past 25 years outside of the US, and currently registered in 60
countries around the world for a variety of indications, Thymoglobuline has 
been an integral part of the immunosuppressive regimen for patients undergoing 
solid organ and allogeneic stem cell transplantation as well as a standard of 
care for patients with aplastic anemia who cannot undergo a stem cell 
transplantation. Thymoglobuline remains an appropriate first-line 
immunosuppressive therapy in the treatment of aplastic anemia based on its 
positive benefit/risk profile in those countries where no horse ATG is 
available.

About Sanofi Oncology
Based in Cambridge, Massachusetts, USA and Vitry, France, Sanofi Oncology is
dedicated to translating science into effective therapeutics that address unmet
medical needs for cancer and organ transplant patients. Starting with a deep
understanding of the disease and the patient, Sanofi Oncology employs 
innovative approaches to drug discovery and clinical development, with the 
ultimate goal of bringing the right medicines to the right patients. We believe
in the value of partnerships that combine our internal scientific expertise 
with that of industry and academic experts.
Our commitment is to help patients live healthier and longer lives through 
novel science and innovative therapies, with a portfolio that includes 11 
marketed products and more than 15 compounds in clinical development, including
small molecules and biological agents. About Sanofi Sanofi, a global and 
diversified healthcare leader, discovers, develops and distributes therapeutic 
solutions focused on patients' needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes solutions, human vaccines, 
innovative drugs, consumer healthcare, emerging markets, animal health and the 
new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York 
(NYSE: SNY).

Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and 
potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding 
labelling and other matters that could affect the availability or commercial 
potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group's ability to benefit 
from external growth opportunities, trends in exchange rates and prevailing 
interest rates, the impact of cost containment policies and subsequent changes 
thereto, the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by Sanofi, 
including those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2011. Other than as required by applicable law, Sanofi does 
not undertake any obligation to update or revise any forward-looking 
information or statements.
                                     # # #

Contacts:

Sanofi
Media Relations                                  Investor Relations
Marisol Péron                                    Sébastien Martel
Tél. : + (33) 1 53 77 45 02                      Tél. : + (33) 1 53 77 45 45
marisol.peron@sanofi.com                         ir@sanofi.com 

Lauren Musto
Oncology Division Communications
Tel: 1(617) 768-1993 ; Mobile 1(781) 572-1147 
lauren.musto@sanofi.com

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Dec/03/2012 08:15 GMT